Wall Street brokerages expect that Tilray Inc (NASDAQ:TLRY – Get Rating) will announce sales of $163.15 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Tilray’s earnings, with estimates ranging from $160.00 million to $169.10 million. The business is expected to announce its next earnings results on Monday, May 9th.
On average, analysts expect that Tilray will report full-year sales of $663.93 million for the current financial year, with estimates ranging from $648.85 million to $704.19 million. For the next financial year, analysts forecast that the company will report sales of $775.44 million, with estimates ranging from $705.20 million to $860.69 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Tilray.
Tilray (NASDAQ:TLRY – Get Rating) last posted its quarterly earnings results on Monday, January 10th. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.12. Tilray had a negative net margin of 66.64% and a negative return on equity of 2.57%. The firm had revenue of $155.10 million for the quarter, compared to analyst estimates of $171.57 million. The company’s revenue was up 19.8% compared to the same quarter last year.
Several research analysts recently commented on the stock. Alliance Global Partners cut their price target on shares of Tilray from $12.00 to $7.00 in a report on Friday, January 7th. Zacks Investment Research upgraded shares of Tilray from a “sell” rating to a “hold” rating in a report on Wednesday, December 22nd. MKM Partners lowered their price objective on shares of Tilray from $10.00 to $8.00 and set a “neutral” rating for the company in a research report on Tuesday, January 11th. Cantor Fitzgerald lowered their price objective on shares of Tilray from $11.80 to $7.40 and set a “neutral” rating for the company in a research report on Friday, January 7th. Finally, Barclays began coverage on shares of Tilray in a research report on Thursday, November 18th. They issued an “underweight” rating and a $10.00 price objective for the company. One research analyst has rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $11.54.
NASDAQ TLRY opened at $5.91 on Thursday. Tilray has a one year low of $5.15 and a one year high of $31.34. The company’s 50 day moving average price is $6.69 and its 200 day moving average price is $9.84. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.51 and a current ratio of 2.25. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of -3.09 and a beta of 2.39.
Several hedge funds have recently added to or reduced their stakes in TLRY. 1832 Asset Management L.P. acquired a new stake in shares of Tilray during the second quarter worth approximately $29,000. Banque Cantonale Vaudoise grew its position in shares of Tilray by 157.6% during the third quarter. Banque Cantonale Vaudoise now owns 2,602 shares of the company’s stock worth $29,000 after buying an additional 1,592 shares in the last quarter. Concord Wealth Partners acquired a new stake in shares of Tilray during the fourth quarter worth approximately $30,000. Confluence Wealth Services Inc. acquired a new stake in shares of Tilray during the fourth quarter worth approximately $30,000. Finally, Dupont Capital Management Corp acquired a new stake in shares of Tilray during the fourth quarter worth approximately $34,000. 12.09% of the stock is owned by institutional investors and hedge funds.
Tilray Company Profile (Get Rating)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Tilray, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Tilray wasn’t on the list.
While Tilray currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.